<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620308</url>
  </required_header>
  <id_info>
    <org_study_id>07-005523</org_study_id>
    <nct_id>NCT00620308</nct_id>
  </id_info>
  <brief_title>CD-NP in Subjects With Stable Chronic Heart Failure</brief_title>
  <acronym>CD-NP</acronym>
  <official_title>A Human Physiologic Study to Evaluate the Renal and Neurohumoral Effects of a Novel Chimeric Natriuretic Peptide, CD-NP, in Subjects With Stable Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This human physiologic study will evaluate the effects of a new drug called CD-NP in&#xD;
      individuals with stable chronic heart failure, with a focus on evaluating responses of the&#xD;
      kidneys and the hormonal system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD-NP is a novel chimeric natriuretic peptide which was created by combining the 22 amino&#xD;
      acids of human C-type natriuretic peptide (CNP) and the 15-amino-acid C-terminus of&#xD;
      Dendroaspis natriuretic peptide (DNP). The rationale for selecting CNP, a natriuretic peptide&#xD;
      of endothelial cell origin, is that it exhibits predominantly venodilating effects, which may&#xD;
      minimize systemic hypotension. Moreover, its anti-proliferative action is also a highly&#xD;
      desirable property for novel cardiovascular drugs. However, a limitation of CNP is that it&#xD;
      does not exert significant renal actions, whereas, DNP is potently natriuretic and diuretic.&#xD;
      Thus, CD-NP was synthesized with the goal of combining the above complementary profiles of&#xD;
      CNP and DNP into a single chimeric peptide.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess renal, neurohumoral and non-invasive hemodynamic physiologic parameters</measure>
    <time_frame>Within the first 24 to 36 hours of the study and at follow-up visits (days 9 and 30)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Stable Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>CD-NP low-dose study drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CD-NP high-dose study drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD-NP</intervention_name>
    <description>One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours</description>
    <arm_group_label>CD-NP high-dose study drug</arm_group_label>
    <arm_group_label>CD-NP low-dose study drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dextrose 5% in water (the vehicle)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and non-pregnant female subjects, aged 21 or above, with stable chronic HF of&#xD;
             primary cardiac etiology, resting left ventricular ejection fraction (LVEF) â‰¤ 40 %&#xD;
             documented within the last 2 years, and New York Heart Association functional class I&#xD;
             - III symptoms&#xD;
&#xD;
          2. Be willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy or other adverse reactions to exogenous natriuretic peptides (CD-NP or&#xD;
             its components, nesiritide, other natriuretic peptides, or related compounds).&#xD;
&#xD;
          2. Women who are pregnant, or breast-feeding.&#xD;
&#xD;
          3. Having received nesiritide for within 7 days prior to prior to entry into the study.&#xD;
&#xD;
          4. Having received any investigational drug or device within 30 days prior to entry into&#xD;
             the study.&#xD;
&#xD;
          5. Clinically unstable patients (e.g. systolic blood pressure &lt; 90 mmHg, ongoing&#xD;
             requirement for vasopressors or mechanical circulatory support, or mechanical&#xD;
             ventilation).&#xD;
&#xD;
          6. Recent hospitalization for decompensated HF or recent defibrillation for cardiac&#xD;
             resuscitation within 30 days prior to randomization.&#xD;
&#xD;
          7. Prior organ transplantation, being on a waiting list for organ transplantation, or&#xD;
             ongoing requirement for longterm vasoactive support.&#xD;
&#xD;
          8. Patients with guarded prognosis who are unlikely to derive meaningful benefit from&#xD;
             CD-NP.&#xD;
&#xD;
          9. Use of sulfonamides, non-steroidal anti-inflammatory drugs, probenecid, or other drugs&#xD;
             that are known to alter renal function within 5 half-lives prior to the first dose of&#xD;
             CD-NP or placebo.&#xD;
&#xD;
         10. Presence of cardiac lesions or comorbidities that may contraindicate the use of&#xD;
             natriuretic peptides, such as clinically significant cardiac valvular stenosis,&#xD;
             hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis,&#xD;
             primary pulmonary hypertension, or uncorrected congenital heart disease that&#xD;
             contraindicates the use of vasodilators.&#xD;
&#xD;
         11. History of blood pressure &gt; 190/115 mmHg or unexplained syncope within the past 3&#xD;
             months.&#xD;
&#xD;
         12. Symptomatic carotid artery disease, known critical carotid stenosis, or stroke within&#xD;
             the past 3 months&#xD;
&#xD;
         13. Clinically significant renal artery stenosis&#xD;
&#xD;
         14. Baseline hemoglobin &lt; 10.0 g/dL.&#xD;
&#xD;
         15. Serum sodium &lt; 130 mEq/L, potassium &lt; 3.6 mEq/L, or magnesium &lt; 1.7 mEq/L.&#xD;
&#xD;
         16. Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at least 5&#xD;
             times the upper limit of normal or bilirubin at least 3 times the upper limit of&#xD;
             normal&#xD;
&#xD;
         17. Creatinine clearance (CrCl) &lt; 50 ml.min-1.1.73m-2, as calculated by Cockcroft-Gault&#xD;
             formula and adjusted for body surface area within the past year or at screening, or&#xD;
             requirement for dialysis.&#xD;
&#xD;
         18. History of alcohol abuse within the past 6 months.&#xD;
&#xD;
         19. Consumption of a phosphodiesterase-5 inhibitor (sildenafil, vardenafil, or tadalafil)&#xD;
             within 72 hours of receiving CD-NP or placebo.&#xD;
&#xD;
         20. Inability to communicate effectively with study personnel.&#xD;
&#xD;
         21. bmi&gt;38&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C. Burnett, Jr., MD</last_name>
    <role>Study Director</role>
    <affiliation>Mayo Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>February 10, 2008</study_first_submitted>
  <study_first_submitted_qc>February 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>September 7, 2012</last_update_submitted>
  <last_update_submitted_qc>September 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John A. Schirger</investigator_full_name>
    <investigator_title>John Schirger ,MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

